<qa>  What is the first-line treatment for non-Hodgkins lymphom- Determine 12-week overall and complete response rate in patients with indolent non-Hodgkins lymphoma treated with rituximab and yttrium Y 90 ibritumomab tiuxetan as first-line treatment. 